Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study

Leo I. Gordon, Arturo Molina, Thomas Witzig, Christos Emmanouilides, Andrew Raubtischek, Mohamed Darif, Russell J. Schilder, Greg Wiseman, Christine A. White

Research output: Contribution to journalArticlepeer-review

185 Scopus citations


We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for relapsed or refractory CD20+, B-cell, non-Hodgkin lymphoma (NHL). We now provide long-term follow-up data in responding patients based on International Workshop Response Criteria. Complete (CR), CR unconfirmed (CRu), and partial response (PR) rates were 29%, 22%, and 22%, respectively (overall response rate 73%, 51% in CR/CRu). Mean time to progression (TTP) and duration of response (DR) in responders were 12.6 months and 11.7 months, respectively. At the maximum tolerated dose (0.4 mCi/kg [14.8 MBq/kg]), TTP and DR in complete responders (CR/CRu) were 28.3 and 27.5 months, respectively. Nine patients (24% of responding patients) had a TTP of more than 3 years. Long-term responders (> 5 years) have been identified. Ibritumomab tiuxetan produces durable responses in patients with indolent and diffuse large B-cell lymphoma.

Original languageEnglish (US)
Pages (from-to)4429-4431
Number of pages3
Issue number12
StatePublished - Jun 15 2004

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20<sup>+</sup> B-cell lymphoma: Long-term follow-up of a phase 1/2 study'. Together they form a unique fingerprint.

Cite this